• A composite endpoint of reduction in estimated GFR of 30ml/min/1.73mxm in individuals w/a baseline estimated GFR >= 60 ml/min/1.73mxm, reduction in estimated GFR >50% in individuals w/ baseline estimated GFR <60ml/min/1.73mxm; ESRD or death [ Time Frame: up to the last follow-up date of the study ] [ Designated as safety issue: No ]
  

• A renal composite endpoint, defined as; reduction in estimated GFR of >50% (for individuals with baseline GFR <60) or reduction in GFR of >30 (for individuals with baseline GFR >= GFR 60) or ESRD [ Time Frame: up to the last follow-up date of the study ] [ Designated as safety issue: No ]
  

Primary Hypothesis:

To evaluate the combination of an angiotensin converting enzyme inhibitor (ACEI) with an angiotensin receptor blocker (ARB) vs. standard treatment with angiotensin receptor blocker on the progression of kidney disease in individuals with Type 2 diabetes and overt nephropathy.

The primary outcome is a composite endpoint of reduction in estimated GFR of 30 ml/min/1.73mxm in individuals with an estimated GFR greater than or equal to 60 ml/min/1.73mxm; reduction in estimated GFR of greater than 50% in individuals with an estimated GFR less than 60 mL/min/1.73mxm; progression to end-stage renal disease (defined as need for dialysis, renal transplant or an eGFR less than 15 mL/min/1.73mxm) or death.

Secondary outcome: a renal composite endpoint, defined as; reduction in estimated GFR of more than 50% (for individuals with a baseline estimated GFR less than 60 ml/min/1.73mxm); reduction in estimated GFR of more than 30 ml/min/1.73mxm (for individuals with a baseline estimated GFR greater than or equal to 60 ml/min/1.73mxm) or progression to end-stage renal disease (defined as need for dialysis, renal transplant or an eGFR of less than 15 ml/min/1.73mxm).

Tertiary outcomes are cardiovascular events (cardiovascular mortality, myocardial infarction, cerebrovascular accident, admission for heart failure), change in albuminuria at 12 months and decline in slope of kidney function.

Study Abstract:

The study is a multi-center, prospective, randomized, parallel group trial to test the efficacy of the combination of an angiotensin converting enzyme inhibitor (ACEI) with an angiotension receptor blocker (ARB) vs. standard treatment with angiotension receptor blocker on the combined end-point. The primary outcome is a composite endpoint of reduction in estimated GFR of 30 ml/min/1.73mxm in individuals with an estimated GFR greater than or equal to 60 ml/min/1.73mxm; reduction in estimated GFR of greater than 50% in individuals with an estimated GFR less than 60 ml/min/1.73mxm; progression to end-stage renal disease (defined as need for dialysis, renal transplant or en eGFR less than 15 ml/min/1.73mxm)or death. The study population is individuals with type 2 diabetes and overt nephropathy.

Eligible subjects who consent to participate will be randomized into either the combination therapy arm or the mono therapy arm. The randomization will be stratified by site and within sites by baseline albuminuria (< 1 vs. greater than or equal to 1 gram/gram creatinine) and eGFR (< 60 vs. greater than or equal to 60 ml/min/1.73mxm). All participants will receive open label therapy with losartan, an ARB, as standard of care. Patients not treated with an ACEI or ARB will be initiated on losartan; patients treated with an ACEI or ARB other than losartan (the study ARB) will be converted to losartan (the study ARB) and the dose titrated to 100 mg/day. Individuals who continue to meet the eligibility criteria will be randomized in a 1:1 ratio to the addition of blinded lisinopril (the study ACEI) or placebo. The medication (lisinopril or placebo) will be titrated from an initial dose of 10 mg/day to a target dose of 40 mg/day. After each adjustment in dose, serum chemistries will be evaluated for kidney function and potassium levels. Subjects will be enrolled over a three-year period and the maximum length of follow-up is 5 years. The planned study duration is 5 years with 3 years of accrual and 2-5 years of follow-up for all enrolled patients.